No Data
No Data
Henan Taloph Pharmaceutical Stock (600222.SH): The company did not implement share repurchase in August.
As of August 2024, Henan Taloph Pharmaceutical Stock (600222.SH) announced that the company did not implement any share repurchases. As of August 31, 2024, the company has repurchased a total of 4,693,600 shares, accounting for 0.82% of the total share capital of the company. The highest price of the repurchase transaction was 4.97 yuan/share, and the lowest price was 3.82 yuan/share. The total amount paid was 21,274,189.00 yuan (excluding transaction costs). The repurchase of the shares mentioned above complies with the relevant laws and regulations and the requirements of the company's share repurchase program.
Henan Taloph Pharmaceutical (600222.SH): Received a government subsidy of RMB 3.5223 million.
Gelonghui August 30th | Henan Taloph Pharmaceutical Stock (600222.SH) announced that the company and its subsidiaries received a total of 3.5223 million yuan in government subsidies from January 1, 2024 to August 30, 2024, all of which are government subsidies related to income, accounting for 8.09% of the net income attributable to the shareholders of the listed company as audited in the most recent period.
Henan Taloph Pharmaceutical Stock 2024 Interim Report
太龙药业2024年半年度报告摘要
Henan Taloph Pharmaceutical Stock (600222.SH): The net income in the first half of the year was 26.618 million yuan, turning losses into profits year-on-year.
On August 21st, Taloph Pharmaceutical (600222.SH) released its semi-annual report for 2024. During the reporting period, the company achieved a revenue of 0.927 billion yuan, a year-on-year decrease of 6.71%; the net income attributable to shareholders of the listed company was 26.618 million yuan, turning losses into profits year-on-year; the basic earnings per share were 0.0477 yuan. During the reporting period, the net income attributable to the parent company increased by 64.9498 million yuan compared to the same period last year. Excluding the temporary increase in demand for heat-clearing and detoxifying drugs at the beginning of the previous year, which affected the pharmaceutical formulation business, the company's main business sectors have maintained a growth trend. By continuously optimizing the product portfolio and customer structure, the company has strengthened lean management.
Henan Taloph Pharmaceutical Stock (600222.SH): No vitamin-related products currently available.
Henan Taloph Pharmaceutical Stock (600222.SH) stated on the investor communication platform that the company currently does not have any products related to vitamins.
No Data
No Data